Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RS-0625
- Development stage
- Preclinical
- Lead developer
- PDC Therapeutics
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
01
Overview
RS-0625 is an integrin-targeting polymer drug conjugate under preclinical development for oncology indications, specifically ovarian cancer. It is being developed by RS Research (RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.) and PDC Therapeutics. The drug utilizes the Sagitta Bir platform and is classified as a new molecular entity. While its precise mechanism of action has not been fully defined in public sources, it targets integrins, which are cell surface receptors involved in cell adhesion and signaling—processes often dysregulated in cancer progression[1][2][3].
- Other names
- RS 0625RS0625RS-0625
02
Targets
Neuraminidase
Beyond the preview
Go deeper on RS-0625.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RS-0625.